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DISCUSSION PAPER
Diagnosis of asthma and chronic obstructive 
pulmonary disease in general practice
C P VAN SCHAYCK side the Netherlands.4 For example, general practitioners in the
PRIMARY AND SECONDARY CARE RESPIRATORY 
SPECIALISTS WORKING GROUP
SUMMARY. There may be an overlap between the clinical 
pictures of asthma and chronic obstructive pulmonary dis­
ease which hampers a clear distinction between the two dis­
eases. Most symptoms presented by patients do not clearly 
belong exclusively to either asthma or chronic obstructive 
pulmonary disease. By the nature o f their discipline and 
training, general practitioners focus mainly on symptoms 
presented, which do not give a decisive answer in the differ­
ential diagnosis between the two diseases. Therefore, gen­
eral practitioners must rely on objective parameters, such as 
determining the presence and degree of reversibility of air­
way obstruction, diurnal peak flow variability, bronchial 
hyper-responsiveness and allergy. This paper puts forward 
a pragmatic, primary care definition of asthma and chronic 
obstructive pulmonary disease.
Keywords: asthma; infarction; pulmonary differential diag­
nosis; diagnostic techniques; quality in general practice.
Introduction
N diagnosing and treating patients with airflow obstruction, it is 
important to distinguish between asthma and chronic obstruc­
tive pulmonary disease. Chronic obstructive pulmonary disease is 
a collective term for chronic bronchitis and emphysema. Until 
recently, it was common practice in the Netherlands to use the 
umbrella term ‘chronic non-specific lung disease’ for chronic 
obstructive disorders of the lower airways. This description was 
based on the so-called Dutch hypothesis, first put forward in 1961 
and later revised in 1991.2’3
The Dutch hypothesis proposes that there is a (genetic) host 
factor common to both asthma and chronic obstructive pulmonary 
disease, and because there is so much overlap between their clini­
cal pictures, it is not useful to classify patients as having one dis­
ease or the other. Apart from in some epidemiological surveys, 
the term chronic non-specific lung disease has not been used out-
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UK have always used the terms asthma and chronic bronchitis 
separately. There is now clear evidence that the pathogenesis and 
pathophysiology of asthma and chronic obstructive pulmonary 
disease are not the same, and therefore, patients with these condi­
tions should be treated differently.4 There is much evidence indi­
cating that anti-inflammatory and bronchodilator therapies do not 
have the same efficacy in patients with chronic obstructive pul­
monary disease as in patients with asthma: anti-inflammatory 
medication is essential in the treatment of (chronic) asthma, 
whereas this has not yet been shown for patients with chronic 
obstructive pulmonary disease. Longitudinal studies in general 
practice have shown that the two conditions have different prog­
noses: asthma is often fully remittent, especially in childhood, 
whereas the progress of chronic obstructive pulmonary disease 
seems to be irreversible.5
Therefore, it would seem useful to develop practical guidelines 
that made a clear distinction between asthma and chronic obstruc­
tive pulmonary disease. The aim of the discussion paper is to con­
tribute to this process. This paper draws on international consen­
sus reports,1,6,7 and on the Dutch standard on the diagnosis of 
asthma and chronic obstructive pulmonary disease which was 
drawn up by the Dutch Society of Physicians of Pulmonary 
Diseases and Tuberculosis.8 However, most of these reports focus 
on the diagnosis of asthma and chronic obstructive pulmonary 
disease by hospital chest physicians, and thus, cannot easily be 
applied by general practitioners as they commonly refer to techni­
cal equipment that is usually not available in primary care. As far 
as we know, there are no guidelines available for general practi­
tioners to make a clear distinction between asthma and chronic 
obstructive pulmonary disease. Rather than being a consensus 
statement, this paper is presented as a discussion which, it is 
hoped, will stimulate comment and debate.
Diagnosis of asthma
Asthma is characterized by a specific type of inflammation of the 
airways which is expressed clinically as increased airway respon­
siveness to a large number of stimuli. The result is variable air­
way obstruction. The most important symptoms of asthma are 
recurrent periods of coughing, wheezing and dyspnoea, all of 
which may vary considerably in intensity in a patient. Airway 
obstruction can be treated rapidly with a bronchodilator and more 
slowly with an inhaled corticosteroid. Asthma is commonly 
accompanied by allergy. Compared with patients with chronic 
obstructive pulmonary disease, patients with asthma are often 
much younger, are less likely to smoke and have a sudden onset 
of their disease. For a diagnosis of asthma, it is important to 
demonstrate reversibility and increased diurnal variability of air­
way obstruction. Apart from airway hyper-responsiveness, 
reversibility and variability of airway obstruction are generally 
considered to be hallmarks of asthma. General practitioners are 
usually the first to diagnose asthma and they have often been 
accused of underdiagnosis (and therefore undertreatment) of asth­
ma.0 However, there has been increasing evidence that at least 
part of the problem is caused by the patients themselves, who do 
not present their symptoms to general practitioners.111 Therefore, 
general practitioners should be alert: to a patient’s report of, for 
example, a persistent cough. A careful clinical history and objec-
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tive assessments of asthma will help to distinguish ‘normal 
coughing’ from asthma in these subjects.
Determining presence of airway obstruction. Airway obstruction 
can be documented most reliably by means of the forced expirato­
ry volume in one second (FEV,).11 In this respect, obstruction is 
defined as a reduction in FEV, compared with values measured in 
healthy subjects of the same sex, age and height. Predicted values 
established by the European Respiratory Society for healthy west­
ern Europeans are recommended.11 Obstruction is defined as an 
FEV, which is lower than the predicted value minus a fixed value 
in men and women (840 ml in men and 620 ml in women). To 
determine FEV,, a spirometer is needed, and reliable and practical 
portable spirometers range from £400 to £2300.12 The more 
expensive spirometers directly calculate predicted values. 
However, few general practices in the Netherlands and in the UK 
have spirometers as it is currently accepted practice to determine 
airway obstruction using a peak flow meter. There are now sever­
al accurate peak flow rate meters available,13 ranging from £8 to 
£16. Peak expiratory flow rate (peak flow) is more effort depen­
dent and gives less reliable values compared with FEV,. 
Moreover, the peak flow has been shown to be incapable of moni­
toring the progression as FEV, does.
Measuring reversibility of airway obstruction. The percentage 
change in FEV, from baseline value is often used as a measure of 
reversibility of airway obstruction. However, studies have shown 
that this criterion is not effective in distinguishing between 
patients with asthma and patients with chronic obstructive pul­
monary disease.14 Moreover, the response measured is strongly 
dependent on the baseline value.14 A better method of discrimi­
nating between the two conditions is by expressing the change in 
FEV, as a percentage of the predicted value.15 A change in FEV, 
of 9% or greater of the predicted indicates reversibility, although 
reversibility should be considered as a continuous variable and 
each cut-off point remains arbitrary .13 When having their 
reversibility of airway obstruction assessed, patients should 
refrain from taking their short-acting inhaled beta-agonists (e.g. 
salbutamol, terbutaline or fenoterol) for at least 8 h before assess­
ment and long-acting inhaled or oral beta-agonists and theo­
phylline for 12 h before assessment. Reversibility of airway 
obstruction is determined 15 min after the administration of an 
appropriate dose of a short-acting beta-agonist; for example, 400 
jn g salbutamol.
Peak flow
Although peak flow is less accurate than FEV, in determining 
severity of airway obstruction, it is effective in determining
reversibility and variability of airway obstruction in patients with 
asthma. The advantage of measuring reversibility or variability is 
that the patient is his or her own reference because comparison is 
always made with one of his or her own values measured earlier. 
There are reference values in the literature for peak flow mea­
surements, corrected for height, age and sex,11 but they are less 
accurate than those for FEV,. Children from the age of 5 years 
and most adults are capable of performing peak flow measure­
ments. However, this effort-dependent test does require patients 
to have been taught adequately. A patient’s measurements should 
be performed using the same type of peak flow meter16 (if possi­
ble with the same meter) since inter-instrument variations may 
occur.13
Measuring reversibility of airway obstruction. Investigation in 
general practice patients has shown that in a reversibility test an 
absolute change in peak flow of 60 I mill'1 or more cor 
with a change of 9% in FEV. as a percentage of predicted value.17
Measuring diurnal peak flow variability. To determine diurnal 
peak flow variability, peak flow measurements are best performed 
twice a day; for example, 15 min after getting up in the morning 
and then between 10 and 12 h later. Measurements should take 
place at the same times each day and 8 h after the last dose of 
bronchodilator medication. A number of different methods exist 
for calculating diurnal variation in peak flow but the most useful 
is the amplitude percentage mean.18 Diurnal variability is deter­
mined by measuring the peak flow three times in the morning and 
evening (taking the highest value of three measurements) using 
the following formula (where PEF is peak flow):
Diurnal variability (%)
highest PEF -  lowest PEF
mean PEF
X 100
A variability of more than 15% indicates asthma.7 Increased 
variability in bronchial obstruction is always an indication of 
increased instability of the airways and (probably) of airway 
hyper-responsiveness. Patients must measure their peak flow in 
the morning and evening at home for at least 7 days. In many 
cases, measurement of peak flow over a period of one week is 
sufficient to show diagnostic variability, but where diagnosis 
remains in doubt, a trial of oral corticosteroids should be under­
taken, Oral prednisolone 40 mg daily for adults for 14 days and 
30 mg daily for children weighing 15 kg or more, for 5—10 days, 
in conjunction with peak flow measurements should demonstrate 
a rise in baseline peak flow of 15% or more if untreated asthma 
is present.
Airway hyper-responsiveness
Airway hyper-responsiveness is one of the hallmarks of asthma. 
When bronchial hyper-responsiveness is present, obstruction can 
be provoked in response to exposure to bronchoconstrictive irri­
tants of a physical (for example cold air, fog), physiological 
(exercise), chemical (sulphur dioxide) or pharmacological (hista­
mine, methacholine) nature. The severity of the obstruction 
depends on the intensity of the stimulus and the patient’s sensitiv­
ity and reactivity to it.
The sensitivity of the airways is often measured in hospital by 
means of a challenge test. Bronchial hyper-responsiveness is then 
defined as the provocative concentration (PC20) or dose (PD2H) of 
a bronchoconstrictor inhalant required to cause a decrease in 
FEV, of 20% below baseline values. The bronchoconstrictor 
inhalant commonly used is histamine or methacholine, adminis­
tered in doubling concentrations. There is a bronchial hyper- 
responsivenesness when the PC20 is smaller than or equal to 8 mg 
histamine ml-1. Patients with asthma have, by definition, 
bronchial hyper-responsiveness (high sensitivity), but unfortu­
nately, the reverse is not always the case (moderate specificity), 
i.e. not all subjects with bronchial hyper-responsiveness have 
asthma. Epidemiological investigations in the past few years have 
shown that asymptomatic hyper-responsiveness often occurs in 
the general population.19 The clinical significance of this asymp­
tomatic hyper-responsiveness is not yet clear.
A good example of airway obstruction induced by physical 
stimuli is airway constriction after exercise, in which loss of 
water from the surface of the airways is thought to be an impor-
tant cause.*-” Exercise tests can be useful in the diagnosis of asth­
ma in children, in whom exercise-related airway obstruction is a 
commonly occurring symptom.19
Standardization of bronchial challenge tests is essential which 
means that the patient has to be referred to a hospital lung func­
tion laboratory for such a test. In general practice, therefore, 
determination of diurnal peak flow variability as an indication of 
airway ss is t
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Allergy
Asthma is often accompanied by an allergy. The severity of the 
allergic reaction is determined by the dose of inhaled allergen, the 
degree of sensitization and the degree of airway hyper-respon­
siveness. Avoidance of allergens may decrease symptoms, 
improve lung function and decrease airway hyper-responsiveness.
Whether an inhalation allergy is present or not can often be deter­
mined by taking a medical history. This means that the specificity 
of a proper medical history is reasonably good, but that the sensi­
tivity is not sufficient for most allergens. When taking a patient’s 
medical history, it is important to note which allergens the patient
might inhale in his or her own environment (i.e. home, hobby and alveolar walls with loss of lung elasticity, 
work). It also has to be determined if there is a relationship 
between the patient’s symptoms and the level of exposure to van- Spirometry
ease is at an advanced age (older than 40 years) and the progres­
sion is gradual. Long-standing cigarette smoking is the most 
important risk factor.
Chronic obstructive pulmonary disease is a collective term for 
chronic obstructive bronchitis, emphysema and peripheral airway 
obstruction. Chronic obstructive bronchitis is a clinical term 
defined as a chronic or recurrent increase in sputum production 
and coughing occurring daily for 3 months in at least two consec­
utive years, which is accompanied by chronic airway obstruction. 
Emphysema is a pathological term characterized by abnormal 
permanent dilation of the air spaces owing to destruction of the
ous allergens. There may not be an obvious time relationship 
between the inhalation of an allergen an the development of 
symptoms as an inhalation allergy can express itself in a so-called 
late allergic bronchial obstructive reaction 6-8 h after exposure.6,8
If the medical history does not give a decisive answer about the 
presence of an inhalation allergen, a skin prick test could be con­
sidered. An alternative is to use the Phadiatop test, a test com­
monly used by general practitioners in the Netherlands but rarely 
used in the UK. As with the RAST test, a blood sample is taken 
and the serum analysed in a laboratory. The Phadiatop test con­
sists of a composition of the most common allergens and is 
cheaper than the RAST test. Its sensitivity and its specificity are
Determining presence of airway obstruction, As with the diagno­
sis of asthma, airway obstruction in chronic obstructive pul­
monary disease is determined most reliably by FEV,, there being 
obstruction if the FEV, is lower than the predicted value minus 
840 nil in men and 620 ml in women.11 Airway obstruction 
should be recorded on three or more occasions during one year 
despite adequate treatment.8 Peak flow is less suitable for assess­
ing obstruction in chronic obstructive pulmonary disease: in 
patients with emphysema, the initial part of the flow-vo'lume 
curve may be less reduced, so peak flow may not accurately 
assess the degree of airway obstruction.
high.21 However, the Phadiatop test does not indicate to which Measuring reversibility of airway obstruction. In contrast to asth-
allergen the patient is allergic thus the specific inhalation allergen 
must be identified by means of an intracutaneous skin prick test 
or by the RAST-lgE. Skin prick tests are preferable because the 
reactions can be directly read and because this test is cheaper. 
Therefore, the use of RAST-lgE could be restricted to patients 
with eczema. The sensitivity and specificity of the determination 
o f  the total number of eosinophils and the total lgE for an inhala­
tion allergen in patients with asthmatic complaints is low so it has 
no clinical significance in general practice.8
Infants
General practitioners are often reluctant to diagnose wheezing or 
coughing children aged less than 5 years as having asthma. This is 
not without reason: only a small minority of children with acute 
bronchitis or recurrent respiratory tract infections seem to develop 
asthma in adolescence.5 It is not clear from epidemiological stud­
ies whether or not wheezy bronchitis is an early form of asthma. 
Another problem in the diagnosis of asthma in young children is 
that there are few objective tools for the general practitioner to 
use, except for the assessment of allergy. When a specific inhala­
tion allergy has been proven, this may have important conse­
quences for the disease management of these children. We would 
advise general practitioners to monitor closely young children 
with asthma symptoms or acute bronchitis.
ma, chronic obstructive pulmonary disease is characterized by 
restricted or absent reversibility of airway obstruction. Therefore, 
in order to determine chronic obstructive pulmonary disease 
objectively, there should be, simultaneously, airway obstruction 
and an irreversibility of this obstruction. When this disease is sus­
pected, airway reversibility can be determined by giving 40 mg 
ipratropium bromide because most patients with chronic obstruc­
tive pulmonary disease show a greater bronchodilating response 
after ipratropium than after salbutamol.22 However, for compara­
bility and standardization of the test, it is advisable to use the 
same inhalant as in asthma: 400 fig salbutamol. In this case, irre­
versible obstruction is indicated by a change in FEV, of less than 
9% of the predicted value.
Airway hyper-responsiveness
In patients with chronic obstructive pulmonary disease, increased 
airway hyper-responsiveness may be present when measured by a 
histamine or methacholine challenge test. This hyper-responsive­
ness is more a result of pre-existing airway obstruction than of 
inflammation and is directly related to the degree of baseline lung 
function, whereas this is not the case in asthma.2’ As instability of 
the airways plays a much less dominant role in chronic obstruc­
tive pulmonary disease than in asthma, diurnal peak How variabil­
ity will always be less than 15%.
Diagnosis of chronic obstructive pulmonary disease
A lthough international consensus reports on asthma have
appeared in more recent years,6,7 chronic obstructive pulmonary function laboratory, 
disease is characterized by the less-precise definition published with morphologically 
by the American Thoracic Society in 1987.' In this definition, it ment cannot be made with 
is described as a disease characterized by expiratory airway 
obstruction which does not clearly change over a period of some 
months. It is also characterized by coughing and sputum produc­
tion, and by dyspnoea, which may be present at rest or during 
effort. The perception of dyspnoea may decrease with age, but it 
is not clear whether there is a real decrease in the actual symp­
tom or whether patients learn to live with their shortness of 
breath. Usually, the onset of chronic obstructive pulmonary dis-
Emphysema can only be definitely diagnosed in a hospital lung-
capacity seems to correlate well 
emphysema, but this measure-
Distinction between asthma and chronic obstructive 
pulmonary disease
There may be overlap between the clinical pictures of asthma and 
chronic obstructive pulmonary disease which hampers a clear dis-
tinction between the two diseases. Most ; s presented by
patients do not clearly belong exclusively to or
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chronic obstructive pulmonary disease. By the nature of their dis­
cipline and training, general practitioners focus mainly on symp­
toms presented, which do not give a decisive answer in the differ­
ential diagnosis between the two diseases. Therefore, general 
practitioners must rely on objective parameters, such as determin­
ing the presence and degree of reversibility of airway obstruction, 
diurnal peak flow variability, bronchial hyper-responsiveness and 
allergy. A summary of the difference between the two diseases is 
presented in Table 1. We suggest the following pragmatic, prima­
ry care definitions of asthma and chronic obstructive pulmonary 
disease.
Asthma is characterized by the periodic occurrence of one or 
more of the following symptoms established by taking a patient’s 
medical history:
wheezing and/or 
(morning) dyspnoea and/or 
coughing
combined with one or more of the following objective criteria:
reversible airway obstruction (a change of 601 min"1 or more in 
the peak flow or a change of 9% or more in FEV, compared 
with the predicted value after administering 400 /ig salbutamol) 
and/or
diurnal peak flow variability (highest minus lowest peak flow 
divided by the mean peak flow) more than 15%
Chronic obstructive pulmonary disease is characterized by the 
occurrence of one or more of the following symptoms established 
by taking a patient’s medical history:
chronic coughing and/or
•  chronically increased sputum production (both should occur 
daily for three months in at least two consecutive years) and/or
•  effort dyspnoea
combined with the following objective criterion:
•  airway obstruction with little or no reversibility (an airway 
obstruction at least three times in one year, i.e. an FEV. lower 
than the predicted value minus 840 ml in men and 620 ml in
Table 1. Overview of the differences between asthma and chron­
ic obstructive pulmonary disease (COPD) (modified according to 
Vermeire24).
HIM
Factors present in
flAirway obstruction = measured FEV, is less than the predicted value of 
FEV, minus 840 ml in men and 620 ml in women. bReversible airway 
obstruction = 9% or more change in measured FEV. as a percentage of
the predicted value or an absolute change of 60 I min 1 or more in peak
flow after administering 400 pg salbutamol. Airway hyper-responsive- 
ness = PC20 is smaller than or equal to 8 mg m l1 histamine. ‘‘Diurnal 
peak flow  variability = highest minus lowest peak flow divided by the 
mean peak flow is 15% or more.
women with a change in FEV, of less than 9% of the standard 
value after administering 400 ¡lg salbutamol).
Age of patient and age at onset of symptoms, smoking history, 
and allergy may also contribute to the differential diagnosis of the 
two diseases. Characteristic of chronic obstructive pulmonary dis­
ease is a disease onset after the age of 40 years and a gradual pro­
gression, usually after years of moderate or heavy smoking; aller­
gy does not play a role. This is in contrast to asthma, which has its 
peak at a younger age, is commonly accompanied by allergy and 
may be sudden in onset; smoking history is of less relevance.
Diagnosis should err towards asthma whenever there is doubt 
since treatment options are so much greater. Indeed, patients 
should not be labelled as having chronic obstructive pulmonary 
disease without conclusive proof of irreversibility of airway 
obstruction including the use of trials of oral corticosteroids.
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personal fitness and self esteem together with personal counselling.
To receive an information pack please contact:
Mrs Janice Richardson MA, BEd, Headteacher, Pilgrims School, Firle 
Road, Seaford, East Sussex, BN25 2HX. Tel: 01323 892697
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